Premium
Amantadine for levodopa‐induced choreic dyskinesia in compound heterozygotes for GCH1 mutations
Author(s) -
Furukawa Yoshiaki,
Filiano James J.,
Kish Stephen J.
Publication year - 2004
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.20194
Subject(s) - amantadine , levodopa , dyskinesia , dystonia , parkinsonism , medicine , compound heterozygosity , neurological disorder , movement disorders , paroxysmal dyskinesia , pharmacology , psychology , mutation , central nervous system disease , neuroscience , parkinson's disease , genetics , biology , gene , disease
Amantadine suppressed severe levodopa‐induced choreic dyskinesia, which developed at initiation of levodopa therapy, in two siblings manifesting dystonia with motor delay phenotype of GTP cyclohydrolase I deficiency caused by compound heterozygous GCH1 mutations. Our finding suggests a beneficial effect of amantadine on this type of dyskinesia frequently observed in relatively severe dopamine‐deficient metabolic disorders. © 2004 Movement Disorder Society